Loading
A phase 2 trial of Nogapendekin alfa inbakicept, Pembrolizumab, Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by ImmunityBio, Inc., active and no longer recruiting.
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors is a phase 2 interventional study registered as NCT03228667 by ImmunityBio, Inc., with 40 participants planned, started 2018-12-11 and due to reach its primary completion in 2029-08-31. Interventions recorded: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab. Conditions listed: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares ImmunityBio, Nogapendekin alfa inbakicept, Nivolumab, Non-small-cell lung cancer.
Shares Atezolizumab, Durvalumab, Nivolumab, Small-cell lung cancer.
Shares Atezolizumab, Nivolumab, Small-cell lung cancer, Pembrolizumab.
Shares ImmunityBio, Nogapendekin alfa inbakicept, Non-small-cell lung cancer.
Shares ImmunityBio, Nogapendekin alfa inbakicept.
Shares Atezolizumab, Durvalumab, Nivolumab, Melanoma.
Shares Merkel cell carcinoma, Nivolumab, Head and neck squamous cell carcinoma, Melanoma.
Shares Merkel cell carcinoma, Small-cell lung cancer, Melanoma, Non-small-cell lung cancer.